Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group
Research output: Contribution to journal › Journal article › Research › peer-review
OBJECTIVE: Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time.
METHODS: A systematic review assessed design of phase II clinical trials in rheumatoid arthritis.
RESULTS: Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint.
CONCLUSION: The next step is to undertake a systematic review of adaptive designs used in early-phase trials in nonrheumatic conditions.
| Original language | English |
|---|---|
| Journal | Journal of Rheumatology |
| Volume | 46 |
| Issue number | 10 |
| Pages (from-to) | 1406-1408 |
| Number of pages | 3 |
| ISSN | 0315-162X |
| DOIs | |
| Publication status | Published - Oct 2019 |
- Adaptive trial design, Early-phase clinical trial, Omeract core outcome set, Rheumatoid arthritis, Systematic review
Research areas
ID: 58098123